Get the Stockscreener App
32.93
0.09%
-0.03
After Hours:
33.25
0.32
+0.97%
Exelixis Inc stock is traded at $32.93, with a volume of 2.08M.
It is down -0.09% in the last 24 hours and down -2.28% over the past month.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$32.96
Open:
$33.22
24h Volume:
2.08M
Relative Volume:
0.91
Market Cap:
$9.40B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
21.11
EPS:
1.56
Net Cash Flow:
$404.94M
1W Performance:
-3.52%
1M Performance:
-2.28%
6M Performance:
+41.51%
1Y Performance:
+50.43%
1-Day Range:
$32.73
$33.32
1-Week Range:
$31.90
$33.59
52-Week Range:
$20.02
$37.59
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
32.93 | 9.40B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001 - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight - MSN
Smith Group Asset Management LLC Acquires Shares of 9,150 Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $36.06 - MarketBeat
Exelixis's SWOT analysis: cancer drug maker's stock faces patent cliff, pipeline promise - Investing.com
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis patent discloses USP1 inhibitors for cancer - BioWorld Online
Exelixis Sets Date for Major 2024 Performance Reveal: Key Details Inside - StockTitan
Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - Inkl
EXEL: Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - StockNews.com
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges By Investing.com - Investing.com Australia
Exelixis (EXEL) Projected to Post Earnings on Tuesday - MarketBeat
Exelixis (NASDAQ:EXEL) Given Equal Weight Rating at Stephens - Defense World
Exelixis (NASDAQ:EXEL) Given New $43.00 Price Target at Truist Financial - Defense World
Exelixis (NASDAQ:EXEL) Rating Increased to Overweight at Morgan Stanley - Defense World
Exelixis (NASDAQ:EXEL) Given “Buy” Rating at HC Wainwright - Defense World
Exelixis downgraded by Oppenheimer to perform - MSN
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight By Investing.com - Investing.com Canada
Morgan Stanley Upgrades Exelixis (EXEL) - MSN
Stifel maintains hold rating, $30 target on Exelixis stock - MSN
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform - Nasdaq
Exelixis (NASDAQ:EXEL) Price Target Raised to $43.00 - MarketBeat
Truist raises Exelixis stock target to $43 on Zanza optimism - MSN
Exelixis (NASDAQ:EXEL) Receives "Equal Weight" Rating from Stephens - MarketBeat
Truist raises Exelixis stock target to $43 on Zanza optimism By Investing.com - Investing.com UK
H.C. Wainwright maintains $40 target on Exelixis stock - Investing.com India
HC Wainwright Reaffirms "Buy" Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Exelixis stock holds Market Outperform rating, $41 target - MSN
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Exelixis, Inc. (NASDAQ:EXEL) Stake Boosted by Nisa Investment Advisors LLC - Defense World
Park Avenue Securities LLC Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Nisa Investment Advisors LLC Increases Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
8,301 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by DGS Capital Management LLC - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Exchange Traded Concepts LLC - MarketBeat
UMB Bank n.a. Purchases 553 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis's SWOT analysis: cabozantinib strength, pipeline potential drive stock - MSN
Exelixis (NASDAQ:EXEL) Rating Lowered to “Market Perform” at Oppenheimer - Defense World
Exelixis (NASDAQ:EXEL) Stock Price Down 5.6%Here's Why - MarketBeat
Exelixis Cancer Drug Trial Shows Promising Survival Benefits in Colorectal Cancer Study - StockTitan
Exelixis falls after ASCO releases colorectal cancer data - MSN
Exelixis Cancer Drug Shows 50% Risk Reduction in Phase 3 GI NET Trial - StockTitan
Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33? - GuruFocus.com
Exelixis Faces Critical Crossroads: What’s Next? - Jomfruland.net
Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns - Yahoo Finance
Exelixis (NASDAQ:EXEL) Downgraded to "Market Perform" Rating by Oppenheimer - MarketBeat
Inspire Investing LLC Purchases 7,331 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Merit Financial Group LLC Invests $437,000 in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Merit Financial Group LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):